• Skip to primary navigation
  • Skip to main content
  • Skip to footer

Target ALS

Leading global ALS research nonprofit breaking down barriers to find effective treatments

  • DONATE
  • About Us
    • Our Mission
    • Our Model
    • Our Impact
    • Our Founder
    • Our Team
    • Our Partners
  • For Scientists
    • Research Cores
      • Target ALS Data Engine
      • Longitudinal Biofluids Core
      • Human Postmortem Tissue Core
      • Stem Cell Core
      • Reagents Core
      • Animal Models Core
    • Funding Opportunities
    • Funded Projects
    • Annual Meeting
    • Science on Target Blog
    • FAQs for Researchers
  • Understanding ALS
    • About ALS
    • Understanding the Science
      • Glossary
      • FAQ
      • ALS 101
    • Voices of ALS
    • Video Library
  • Take Action
    • Ending ALS Starts with You
    • Support Geoff Greulich
    • The ALS Global Research Initiative (AGRI)
      • Global Natural History Study
      • Community Based Pop-Up Clinics
    • Fundraise for ALS Research
    • Ways to Give
    • Email Sign Up
    • Contact Us
    • Donate Now
  • News
    • Announcements
    • In the News
    • Newsletters & Reports

Science on Target

Driving Urgency and Hope: Dr. Björn Oskarsson on Biofluids, Biomarkers, and the Future of ALS Research

Gagan Moorthy · Jun 12, 2025 ·

Rethinking “Junk” DNA: Yini Li’s Bold Bet on RNA, Epigenetics, and ALS

Gagan Moorthy · Jun 12, 2025 ·

Charting the Future of ALS Trials with Digital Twins: A Conversation with Dr. Robert McFarlane

Gagan Moorthy · Jun 5, 2025 ·

A Personal Mission, A Global Lens: Dr. Senda Ajroud-Driss on the Promise of ALS Research

Gagan Moorthy · Jun 5, 2025 ·

Biomarkers: Pioneering Non-Invasive Tools for TDP-43 Detection

Gagan Moorthy · Jun 5, 2025 ·

Expanding ALS Research: Target ALS Global Natural History Study Launches in Israel

Gagan Moorthy · May 27, 2025 ·

Dr. Manish Raisinghani: Insights from the 2025 Target ALS Annual Meeting

Gagan Moorthy · May 27, 2025 ·

Tackling TDP-43: A Systems-Level Approach to A Central Pathological driver of ALS

Gagan Moorthy · May 22, 2025 ·

Trailblazing a New Frontier in ALS Treatment: Dr. Claire Clelland’s Bold CRISPR Strategy to Rewrite the Future

Gagan Moorthy · May 19, 2025 ·

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Interim pages omitted …
  • Page 15
  • Go to Next Page »

Footer

Target ALS
  • Donate
  • Contact
  • Financial Reports
  • Call For Proposals
  • Annual Meeting
  • Privacy Policy
  • Credits

Follow Us

We are a 501(c)(3) public charity (EIN: 81-0756743), eligible to receive tax-deductible contributions that directly support our mission to break down barriers to ALS research to find effective treatments.

The Target ALS (TALS) website is intended for informational purposes only. Opinions expressed may not be that of TALS or its employees. For more information about our digital policies, click here.

© 2023 Target ALS Foundation, Inc.
Target ALS Foundation
244 Madison Avenue #1025
New York, NY 10016
(332) 333-4140
Steck Insights WordPress Consulting